Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Universita di Verona
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 years of age,active but clinically stable plaque psoriasis involving at least 10 percent of the body surface area and a psoriasis area and severity index (PASI) score ≥10 and a body mass index ≥30.
You may not be if
Other type of psoriasis (guttate, erythrodermic and pustular psoriasis)
Uncontrolled hypertension
Severe congestive heart failure
Renal and liver impairment
Active or chronic infections, including HIV, HBV and HCV infections, latent tuberculosis
Previous or active malignancies
Pregnancy and lactations
Previous treatment with cyclosporine
Phototherapy or any systemic or topical therapy for psoriasis within the previous 4 weeks before enrolment.
Clareo Health | Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial
